vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and PROCORE TECHNOLOGIES, INC. (PCOR). Click either name above to swap in a different company.
PROCORE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($359.3M vs $281.3M, roughly 1.3× Guardant Health, Inc.). PROCORE TECHNOLOGIES, INC. runs the higher net margin — -2.5% vs -45.7%, a 43.2% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 15.7%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 12.4%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
GH vs PCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $359.3M |
| Net Profit | $-128.5M | $-9.1M |
| Gross Margin | 64.6% | 80.1% |
| Operating Margin | -43.0% | 15.5% |
| Net Margin | -45.7% | -2.5% |
| Revenue YoY | 39.4% | 15.7% |
| Net Profit YoY | -15.8% | 72.4% |
| EPS (diluted) | $-1.01 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $359.3M | ||
| Q4 25 | $281.3M | $349.1M | ||
| Q3 25 | $265.2M | $338.9M | ||
| Q2 25 | $232.1M | $323.9M | ||
| Q1 25 | $203.5M | $310.6M | ||
| Q4 24 | $201.8M | $302.0M | ||
| Q3 24 | $191.5M | $295.9M | ||
| Q2 24 | $177.2M | $284.3M |
| Q1 26 | — | $-9.1M | ||
| Q4 25 | $-128.5M | $-37.6M | ||
| Q3 25 | $-92.7M | $-9.1M | ||
| Q2 25 | $-99.9M | $-21.1M | ||
| Q1 25 | $-95.2M | $-33.0M | ||
| Q4 24 | $-111.0M | $-62.3M | ||
| Q3 24 | $-107.8M | $-26.4M | ||
| Q2 24 | $-102.6M | $-6.3M |
| Q1 26 | — | 80.1% | ||
| Q4 25 | 64.6% | 80.1% | ||
| Q3 25 | 64.7% | 79.7% | ||
| Q2 25 | 65.0% | 79.1% | ||
| Q1 25 | 63.3% | 79.1% | ||
| Q4 24 | 61.6% | 81.2% | ||
| Q3 24 | 61.1% | 81.4% | ||
| Q2 24 | 59.1% | 83.1% |
| Q1 26 | — | 15.5% | ||
| Q4 25 | -43.0% | -12.3% | ||
| Q3 25 | -37.3% | -4.4% | ||
| Q2 25 | -45.9% | -9.3% | ||
| Q1 25 | -54.6% | -11.7% | ||
| Q4 24 | -62.4% | -21.9% | ||
| Q3 24 | -61.3% | -12.3% | ||
| Q2 24 | -56.8% | -5.2% |
| Q1 26 | — | -2.5% | ||
| Q4 25 | -45.7% | -10.8% | ||
| Q3 25 | -35.0% | -2.7% | ||
| Q2 25 | -43.0% | -6.5% | ||
| Q1 25 | -46.8% | -10.6% | ||
| Q4 24 | -55.0% | -20.6% | ||
| Q3 24 | -56.3% | -8.9% | ||
| Q2 24 | -57.9% | -2.2% |
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $-1.01 | $-0.25 | ||
| Q3 25 | $-0.74 | $-0.06 | ||
| Q2 25 | $-0.80 | $-0.14 | ||
| Q1 25 | $-0.77 | $-0.22 | ||
| Q4 24 | $-0.90 | $-0.42 | ||
| Q3 24 | $-0.88 | $-0.18 | ||
| Q2 24 | $-0.84 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $386.0M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.2B |
| Total Assets | $2.0B | $2.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $386.0M | ||
| Q4 25 | $378.2M | $768.5M | ||
| Q3 25 | $580.0M | $684.0M | ||
| Q2 25 | $629.1M | $620.9M | ||
| Q1 25 | $698.6M | $566.7M | ||
| Q4 24 | $525.5M | $775.4M | ||
| Q3 24 | $585.0M | $756.9M | ||
| Q2 24 | $933.7M | $735.4M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-99.3M | $1.3B | ||
| Q3 25 | $-354.5M | $1.2B | ||
| Q2 25 | $-305.5M | $1.2B | ||
| Q1 25 | $-250.8M | $1.2B | ||
| Q4 24 | $-139.6M | $1.3B | ||
| Q3 24 | $-60.1M | $1.3B | ||
| Q2 24 | $-1.6M | $1.3B |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.0B | $2.2B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.3B | $2.0B | ||
| Q1 25 | $1.3B | $1.9B | ||
| Q4 24 | $1.5B | $2.1B | ||
| Q3 24 | $1.5B | $2.0B | ||
| Q2 24 | $1.6B | $2.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $76.8M |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $76.8M | ||
| Q4 25 | $-26.4M | $114.9M | ||
| Q3 25 | $-35.4M | $88.5M | ||
| Q2 25 | $-60.3M | $30.8M | ||
| Q1 25 | $-62.7M | $66.0M | ||
| Q4 24 | $-64.5M | $29.1M | ||
| Q3 24 | $-51.1M | $39.3M | ||
| Q2 24 | $-94.0M | $58.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $109.2M | ||
| Q3 25 | $-45.8M | $83.1M | ||
| Q2 25 | $-65.9M | $27.9M | ||
| Q1 25 | $-67.1M | $62.0M | ||
| Q4 24 | $-83.4M | $17.4M | ||
| Q3 24 | $-55.3M | $35.7M | ||
| Q2 24 | $-99.1M | $56.8M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 31.3% | ||
| Q3 25 | -17.3% | 24.5% | ||
| Q2 25 | -28.4% | 8.6% | ||
| Q1 25 | -33.0% | 20.0% | ||
| Q4 24 | -41.3% | 5.8% | ||
| Q3 24 | -28.9% | 12.1% | ||
| Q2 24 | -55.9% | 20.0% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 1.6% | ||
| Q3 25 | 3.9% | 1.6% | ||
| Q2 25 | 2.4% | 0.9% | ||
| Q1 25 | 2.2% | 1.3% | ||
| Q4 24 | 9.4% | 3.9% | ||
| Q3 24 | 2.2% | 1.2% | ||
| Q2 24 | 2.9% | 0.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PCOR
Segment breakdown not available.
